Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

121. Randomised controlled trial: ?-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location

Randomised controlled trial: ?-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location α-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here α-channel and calcium-channel blockers are ineffective as medical expulsive therapy

2015 Evidence-Based Medicine (Requires free registration)

122. Natpara (parathyroid horomone) - To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism

Natpara (parathyroid horomone) - To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Natpara (parathyroid hormone) Company: NPS Pharmaceuticals Inc. Application No.: 125511 Approval Date: 1/23/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

2015 FDA - Drug Approval Package

123. Vitamin D and calcium: a systematic review of health outcomes (update)

Vitamin D and calcium: a systematic review of health outcomes (update) Vitamin D and calcium: a systematic review of health outcomes (update) Vitamin D and calcium: a systematic review of health outcomes (update) Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR, Motala A, Cui M, Perry T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR, Motala A, Cui M, Perry T. Vitamin D and calcium: a systematic review of health outcomes (update) Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 217. 2014 Authors' objectives To systematically summarize the evidence on the relationship between vitamin D alone or in combination with calcium on selected health outcomes included in the earlier review: primarily those related

2014 Health Technology Assessment (HTA) Database.

124. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation

Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation TITLE: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness DATE: 26 June 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Many physicians define constipation as a reduction in the frequency of bowel movements (...) or bulking agents (i.e. psyllium seed husk), osmotic laxatives (i.e. lactulose, sorbitol, polyethylene glycol [PEG]), stimulant laxatives (i.e. sennosides, bisacodyl, sodium picosulfate), and stool softeners (i.e. docusate sodium or calcium). 1,2 In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly 4 and oncology treatments. 5 A paucity of evidence is available to support the use of the stool

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

125. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. (PubMed)

Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Pre-eclampsia and eclampsia are common causes of serious morbidity and death. Calcium supplementation may reduce the risk of pre-eclampsia, and may help to prevent preterm birth.To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (...) (28 March 2013) and contacted study authors for more data where possible. We updated the search in May 2014 and added the results to the 'Awaiting Classification' section of the review.Randomised controlled trials (RCTs) comparing high-dose (at least 1 g daily of calcium) or low-dose calcium supplementation during pregnancy with placebo or no calcium.We assessed eligibility and trial quality, extracted and double-entered data.High-dose calcium supplementation (≥1 g/day)We included 14 studies

Full Text available with Trip Pro

2014 Cochrane

126. Calcium channel blockers for inhibiting preterm labour and birth. (PubMed)

Calcium channel blockers for inhibiting preterm labour and birth. Preterm birth is a major contributor to perinatal mortality and morbidity, affecting around 9% of births in high-income countries and an estimated 13% of births in low- and middle-income countries. Tocolytics are drugs used to suppress uterine contractions for women in preterm labour. The most widely used tocolytic are the betamimetics, however, these are associated with a high frequency of unpleasant and sometimes severe (...) maternal side effects. Calcium channel blockers (CCBs) (such as nifedipine) may have similar tocolytic efficacy with less side effects than betamimetics. Oxytocin receptor antagonists (ORAs) (e.g. atosiban) also have a low side-effect profile.To assess the effects on maternal, fetal and neonatal outcomes of CCBs, administered as a tocolytic agent, to women in preterm labour.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (12 November 2013).All published and unpublished

Full Text available with Trip Pro

2014 Cochrane

127. Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial (PubMed)

Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial To determine whether children with calcium-deficiency rickets have a better response to treatment with vitamin D and calcium than with calcium alone.Randomised controlled trial.Jos University Teaching Hospital, Jos, Nigeria.Nigerian children with active rickets treated with calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) were, in addition, randomised to receive either oral (...) (56.4±17.2 nmol/L) than in those who did not (37.7±18.5 nmol/L, p<0.001).In children with calcium-deficiency rickets, there is a trend for vitamin D to improve the response to treatment with calcium carbonate as limestone, independent of baseline 25(OH)D concentrations.ClinicalTrials.gov NCT00949832.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Full Text available with Trip Pro

2014 EvidenceUpdates

128. Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion

Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion UTCAT2663, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion Clinical Question In the adult population, does the fortification of calcium to fruit juice reduce enamel erosion as compared to those without calcium? Clinical Bottom Line Results show juices fortified (...) with a calcium compound have the potential to significantly lower the chances of enamel erosion compared to pure juices; however, more evidence is needed to support application clinically. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Scaramucci/2011 80 bovine enamel specimens in various solutions undergoing erosion, demineralization and remineralization. In vitro animal study Key results The specimens

2014 UTHSCSA Dental School CAT Library

129. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis (PubMed)

Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis We sought to evaluate the impact of coronary artery calcium (CAC) in individuals at the extremes of risk factor (RF) burden.6698 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) were followed for coronary heart disease (CHD) events over mean 7.1 ± 1 years. Annualized CHD event rates were compared among (...) the absence of CAC, even among those with many RF, is associated with a low event rate. Coronary artery calcium has the potential to further risk stratify asymptomatic individuals at the extremes of RF burden.Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com.

Full Text available with Trip Pro

2014 EvidenceUpdates

131. Systematic review: Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour

Systematic review: Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Article Text Therapeutics Systematic review Calcium channel

Full Text available with Trip Pro

2014 Evidence-Based Medicine (Requires free registration)

132. Cohort study: Calcium supplements associated with increased risk of cardiovascular death in men but not women

Cohort study: Calcium supplements associated with increased risk of cardiovascular death in men but not women Calcium supplements associated with increased risk of cardiovascular death in men but not women | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium supplements associated with increased risk of cardiovascular death in men but not women Article Text Primary health care Cohort study Calcium supplements associated with increased

2014 Evidence-Based Nursing

133. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness

Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness CADTH Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There remains a paucity of good quality evidence to support the use of docusate

2014 Health Technology Assessment (HTA) Database.

134. Cohort study: Daily calcium intake in excess of 1400?mg is associated with increased all-cause and cardiovascular disease mortality in women

Cohort study: Daily calcium intake in excess of 1400?mg is associated with increased all-cause and cardiovascular disease mortality in women Daily calcium intake in excess of 1400 mg is associated with increased all-cause and cardiovascular disease mortality in women | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily calcium intake in excess of 1400 mg is associated with increased all-cause and cardiovascular disease mortality

2014 Evidence-Based Nursing

135. Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK

Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK | Great Ormond Street Hospital Google Tag Manager Navigation Search Search You are here Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D (...) for children and young people with neuromuscular disorders in the UK Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK ). Children with reduced exposure to sunlight (such as those who have poor mobility, those with clothing that limits exposure ( ). Children (particularly those with Duchenne Muscular Dystrophy) who are at increased risk of fracture as a result of long term steroid use ( ). Children

2014 Great Ormond Street Hospital

136. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. (PubMed)

Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. Calcium-channel blockers are metabolized by the cytochrome P450 3A4 (CYP3A4; EC 1.14.13.97) enzyme. Blood concentrations of these drugs may rise to harmful levels when CYP3A4 activity is inhibited. Clarithromycin is an inhibitor of CYP3A4 and azithromycin is not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically important drug interactions.To characterize the risk (...) of acute adverse events following coprescription of clarithromycin compared with azithromycin in older adults taking a calcium-channel blocker.Population-based retrospective cohort study in Ontario, Canada, from 2003 through 2012 of older adults (mean age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedipine, diltiazem, or verapamil).Hospitalization with acute kidney injury (primary

Full Text available with Trip Pro

2013 JAMA

137. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation (PubMed)

Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prominent. We therefore aimed to demonstrate a beneficial (...) effect on bone density of the bisphosphonate risedronate in osteopenic Crohn's disease patients.This double-blind, placebo-controlled randomised trial of risedronate with calcium and vitamin D supplementation was performed in osteopenic Crohn's disease patients. Patients were treated for 2 years with follow-up after 3 and after every 6 months. Disease characteristics and activity and bone turnover markers were assessed at all visits; dual x-ray absorptiometry was performed at baseline, 12 and 24

2013 EvidenceUpdates

138. Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events. (PubMed)

Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events. Coronary artery calcium (CAC), measured by computed tomography (CT), has strong predictive value for incident cardiovascular disease (CVD) events. The standard CAC score is the Agatston, which is weighted upward for greater calcium density. However, some data suggest increased plaque calcium density may be protective for CVD.To determine the independent associations of CAC volume and CAC density with incident

Full Text available with Trip Pro

2013 JAMA

139. Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones (PubMed)

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones Higher urinary uric acid excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo (...) , would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation.In this 6-month, double-blind, multicenter, randomized controlled trial, hyperuricosuric participants with a recent history of calcium stones and one or more radio-opaque calcium stone ≥ 3 mm (as seen by multidetector computed tomography) received daily febuxostat at 80 mg, allopurinol at 300 mg, or placebo. The primary end point was percent change from baseline to month 6 in 24-hour urinary uric acid

Full Text available with Trip Pro

2013 EvidenceUpdates

140. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta (...) -analysis Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT CRD summary This review concluded that non-calcium-based phosphate binders were associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease. This was a generally well-conducted review but the conclusions seem overly strong. Authors' objectives To update a prior meta-analysis that compared the effect of calcium

2013 DARE.